• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Magellan widens lead test recall

June 7, 2017 By Sarah Faulkner

Magellan Diagnostic's LeadCareThe FDA this week expanded its Class I recall of lead poisoning tests from Magellan Diagnostics to include 2 additional testing systems.

The regulatory watchdog said it recalled Magellan’s LeadCare testing systems because they may underestimate blood lead levels and provide inaccurate results with venous blood samples.

“Falsely lower test results may lead to improper patient management and treatment for lead exposure or poisoning,” the FDA wrote. “The use of affected product may cause serious adverse health consequences.”

The expanded recall now includes the company’s LeadCare, LeadCare II, Ultra and Plus systems. The latest communication from the FDA said the 7 million affected products were manufactured from Sept. 2013 to present day and were distributed between Jan. 2014 and May 2017.

Meridian Bioscience (NSDQ:VIVO), Magellan’s parent company, pointed out in a statement that the FDA’s recall only applies to venous blood samples and that the systems can still be used with capillary blood samples.

“Approximately 10% of Magellan’s revenue and approximately 1% of Meridian’s overall revenue is derived from venous blood draws,” Meridian said. “We continue to work with the FDA and do not expect this occurrence to cause any material adverse effect to Meridian’s financial results. Meridian and Magellan continue to take these matters very seriously and continue to work closely and fully with the FDA and CDC to address the concerns identified with venous samples as quickly as possible.”

The FDA added that it is working with the Center for Disease Control and Prevention to determine why the tests are inaccurate.

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Recalls Tagged With: magellandiagnostics, meridianbioscience

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS